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We have previously reported that glucose metabolism mediates the eﬀects of insulin to increase leptin gene expression and leptin
secretion by isolated adipocytes. The aim of the present study was to investigate the role of transcription and translation in the
regulation of basal and insulin-stimulated leptin production. The short-term (4 h) and long-term (24–48 h) eﬀects of actinomycin D,
a transcriptional inhibitor, and cycloheximide, an inhibitor of protein synthesis, on leptin gene expression and leptin secretion by
isolated adipocytes were determined. Actinomycin D (5 lg/ml) increased both basal and insulin-stimulated (1.6 nM) leptin secretion
at 4 and 24 h (193 14.9% and 153.8 10.4% of respective controls at 24 h, both p < 0:001). Similar eﬀects of actinomycin D were
observed on basal and insulin-stimulated leptin mRNA levels. 5,6-Dichlororibofuranosyl benzimidazole (DRB), another inhibitor
of transcription, also increased basal (175.4 18.2% of control; p < 0:01) and insulin-stimulated leptin secretion (141.0 11.1% of
insulin-treated cells; p < 0:05) at 24 h. The eﬀect of actinomycin D and DRB to increase basal leptin secretion observed at 4 and 24 h
was not present at 48 h when actinomycin D and DRB both markedly inhibited insulin-stimulated leptin secretion (to 36 16%,
p < 0:05 and 21.9 5.6% of control, for actinomycin D and DRB, respectively, both p < 0:001). Neither actinomycin D nor DRB
had any eﬀect on adipocyte glucose utilization between 24 and 48 h. The observed eﬀects of inhibitors of transcription on leptin gene
expression and leptin secretion are consistent with a long-term transcriptional mechanism for insulin-stimulated glucose metabolism
to increase leptin production. Cycloheximide treatment (10 lg/ml) abolished the eﬀects of insulin to stimulate leptin secretion
(29 11% of control, p < 0:01) during the ﬁrst 4 h of treatment and at all later time points, which indicate that de novo protein
synthesis is required for insulin-mediated glucose metabolism to increase leptin secretion.
 2003 Elsevier Inc. All rights reserved.
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volved in the regulation of body weight via its central
actions on food intake and energy expenditure [1]. Cir-
culating leptin concentrations decrease, independently
of body adiposity, after fasting or caloric restriction in
both humans [2,3] and rodents [4] and the decreases of
leptin are proportional to changes of plasma insulin and* Corresponding author. Fax: 1-530-752-1297.
E-mail address: pjhavel@ucdavis.edu (P.J. Havel).
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concentrations are markedly decreased in insulin-deﬁ-
cient diabetic animals [5,6]. The decreases of leptin ex-
pression and circulating leptin in insulin-deﬁcient
diabetes are reversed by insulin administration in pro-
portion to the degree of glucose lowering [6,7]. These
data provide evidence of a role for insulin and glucose to
mediate changes of leptin production in vivo [8,9].
Several in vitro studies have also shown that insulin
potently stimulates leptin secretion in cultured adipo-
cytes [10,11]. Previously published experiments from our
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metabolism mediates the eﬀect of insulin to stimulate
leptin gene expression and leptin secretion [12]. Thus,
the eﬀect of insulin to increase adipocyte glucose utili-
zation is likely to contribute to insulin-stimulated leptin
production. A recent study in humans also suggests that
increased leptin secretion during glucose and insulin
infusion is mediated by insulin’s actions to increase
glucose metabolism rather than to an eﬀect of insulin
per se [13].
The biochemical and molecular mechanisms under-
lying the eﬀects of glucose and insulin to increase leptin
production have not been identiﬁed. Several investiga-
tors have reported that leptin gene mRNA expression is
increased after insulin treatment both in vivo and in vitro
[7,14,15] or in response to glucose administration in
rodents [14]. A recent study has also shown that insulin
and glucose increase leptin mRNA expression in
abdominal subcutaneous tissue in humans [16]. These
studies suggest that the regulation of leptin production
by insulin and glucose occurs at the level of transcription.
Accordingly, it has been shown that insulin increases the
transcriptional activity of leptin promoter in isolated
adipocytes [17] and that this activation is mediated by
increased glucose metabolism [18]. Other studies, how-
ever, have suggested that post-transcriptional mecha-
nisms may also be involved in the short-term eﬀects of
insulin to stimulate leptin secretion [19,20]. A recent
paper described a dual action of insulin on leptin secre-
tion with an early (less than 48 h) inhibitory action fol-
lowed (48–96 h) by a clear-cut stimulation. In addition, it
was reported that these eﬀects were not mediated by
changes in leptin gene expression, suggesting that it
involved a post-transcriptional mechanism [21].
In the current study, we try to better elucidate the roles
of transcriptional and post-transcriptional mechanisms
in the actions of insulin-mediated glucose metabolism to
increase leptin gene expression and protein secretion.
Several previous experiments examining the molecular
mechanisms by which glucose and insulin increase leptin
production have employed inhibitors of transcription
and translation. However, in most experiments, the ac-
tions of these agents have been investigated over a short
period of time (2 h) [19,20]. In the present studies, we
examined and compared both the short-term (4 h) and
long-term (24–48 h) eﬀects of two transcriptional inhibi-
tors, (actinomycin D and DRB) and an inhibitor of
protein synthesis (cycloheximide), on basal and insulin-
stimulated leptin secretion and leptin gene expression.Materials and methods
Adipocyte isolation and culture. Adipocytes were isolated from
epididymal fat pads of nonfasted male Sprague–Dawley rats (3–4
months). The fat pads were minced in Krebs–Ringer Hepes buﬀer (pH7.4; containing 5mM D-glucose, 2% BSA, 135mM NaCl, 2.2mM
CaCl2  2H2O, 1.25mM MgSO4  7H2O, 0.45mM KH2PO4, 2.17mM
Na2HPO4, and 10mM Hepes). Adipose tissue fragments were digested
in the same buﬀer with type I collagenase (1.25mg/ml per 0.5 g tissue;
Worthington, Lakewood, NJ) at 37 C with gentle shaking at 60
cycles/min for 30min.The resulting cell suspension was diluted in
Hepes-phosphate buﬀer and the isolated adipocytes were then sepa-
rated from the undigested tissue by ﬁltration through a 400-lm nylon
mesh and washed three times. Isolated adipocytes were then resus-
pended in DMEM supplemented with 1% FBS and incubated for
30min at 37 C.
The isolated adipocytes (150ll of 2:1 ratio of packed cells to me-
dium) were then plated on 500ll of a collagen matrix (Vitrogen 100,
Cohesion Technologies, Palo Alto, CA) in 6-well culture plates. After a
45min incubation at 37 C, culture media containing the diﬀerent
treatments were added and the cells were maintained in an incubator at
37 C in 6% CO2 for up to 48 h.
Aliquots (300 ll) of the media were collected at 4, 24, and 48 h, and
replaced with fresh medium containing the appropriate concentration
of insulin (1.6 nM), actinomycin D, DRB, and/or cycloheximide.
Leptin and glucose assay. Leptin concentrations in the medium were
determined by a radioimmunoassay for rat leptin as previously de-
scribed [22] (Linco Research, St. Charles, MO). Glucose was measured
with a YSI glucose analyzer (Model 2300, Yellow Springs Instruments,
Yellow Springs, OH).
RNA preparation and Northern blot analysis. Leptin mRNA was
determined by Northern blotting. The leptin cDNA probe was a
388-bp fragment of mouse leptin cDNA (kindly provided by
Dr. Charles Mobbs, Mount Sinai School of Medicine, New York).
The 18S ribosomal probe was obtained from Ambion (Ambion,
Austin, TX).
RNA was extracted according to the Gibco Life Technologies
procedure using Trizol (Life Technologies, Grand Island, NY). UV
absorbance and integrity gels were used to estimate RNA. Leptin and
18S cDNA probes were labeled by random priming (Rediprime kit,
Amersham, Buckinghamshire, UK) in the presence of [32P]dCTP
(3000Ci/mmol, Amersham). Unincorporated nucleotides were
removed using NucTrap probe puriﬁcation columns (Stratagene, La
Jolla, CA). For each tissue sample, 5–7lg of total RNA was frac-
tionated by electrophoresis on a denaturing 1% agarose gel con-
taining 2.2M formaldehyde and 1 Mops running buﬀer. One
microliter of a 50 lg/ml ethidium bromide (Gibco BRL, Gaithers-
burg, MD) stock solution was added in order to check RNA integrity
and even loading. After electrophoresis, RNA was transferred to
nylon membrane (Duralon-UV, Stratagene, La Jolla, CA) by over-
night capillary transfer and UV cross-linked (Stratalinker 1800,
Stratagene, La Jolla, CA). Blots were then hybridized for 1 h at 68 C
in presence of the labeled cDNA probe (2 106 cpm/ml Express Hyb
solution, Clontech, Palo Alto, CA). After washing at high stringency,
blots were exposed to X-ray ﬁlms with an intensifying screen for 1
day at )80 C. After analysis of leptin mRNA using a single-stranded
cDNA probe followed by quantiﬁcation of bands from ﬁlm, the blots
were re-analyzed using a probe complementary to mouse 18S ribo-
somal RNA, to allow loading of equal mass of RNA in each well.
Leptin mRNA was then normalized with respect to the 18S ribo-
somal signal.
Data analysis. Glucose utilization was determined by subtracting
the glucose concentration measured during the incubations from the
initial media glucose concentration. Glucose utilization was corrected
for the amount of glucose that was removed during each medium
sampling and the amount added by the replacement of fresh media
(15% of total volume).
The eﬀects of the inhibitors in each adipocyte suspension prepared
from a single animal were compared to a control well from the same
suspension. Data are expressed as meansSEM. Data were analyzed
by ANOVA followed by a Bonferroni’s post hoc test (GraphPad
Prism, GraphPad Software, San Diego, CA).
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Eﬀects of actinomycin D on basal and insulin-stimulated
leptin secretion
Fig. 1A depicts both short (4 h) and long-term (24–
48 h) eﬀects of actinomycin D (5 lg/ml) on basal and
insulin-stimulated leptin secretion in isolated rat
adipocytes. In the absence of insulin, leptin release from
the adipocytes (control group) increased between 4 and
48 h. The eﬀects of actinomycin D (5 lg/ml) on basal
leptin secretion were time-dependent. At 4 h of incuba-
tion, actinomycin D induced a slight but nonsigniﬁcant
increase in basal leptin secretion (126% of control). This
stimulation of basal leptin secretion by actinomycin D
was very signiﬁcant after 24 h of treatment (193 14.9%
of control, p < 0:001). After 48 h of treatment, a sig-
niﬁcant (p < 0:001) but less potent stimulatory eﬀect
(168.7 11.9%) of actinomycin D on cumulative leptin
secretion was still observed. However, the amount of
leptin secreted between the 24 and 48 h of treatment was
similar for control and actinomycin D treated adipo-
cytes (Fig. 1B). Thus, the stimulatory eﬀect of actino-
mycin D on basal leptin secretion is not present after
24 h.
As expected, insulin (1.6 nM) induced an increase in
leptin secretion from 4 to 48 h of treatment (Fig. 1A).
Treatment with insulin and actinomycin D for 4 h in-Fig. 1. Eﬀects of actinomycin D on basal and insulin-stimulated leptin
secretion. (A) Time-response eﬀects from 4 to 48 h of treatment. (B)
Changes in basal and insulin-stimulated leptin secretion between 24
and 48 h of treatment. Cultured adipocytes were incubated for up to
48 h in the absence or presence of insulin (1.6 nM) with actinomycin D
(5lg/ml). N ¼ 16 in all groups at 4, 24, and 48 h. ***p < 0:001 com-
pared to basal control. c: p < 0:001 compared with the 1.6 nM insulin-
treated control.duced a slight, but nonsigniﬁcant increase of leptin se-
cretion. Similar to what was observed with basal leptin
secretion, 24 h of actinomycin treatment increased
insulin-stimulated leptin secretion (153.8 10.4% of
insulin-treated cells, p < 0:001). However, during 24–
48 h of treatment this eﬀect was reversed. As shown in
Fig. 1B, from 24 to 48 h, actinomycin D completely
prevented the eﬀect of insulin to stimulate leptin secre-
tion, and leptin production was similar to that observed
in the absence of insulin.
Eﬀects of actinomycin D on leptin gene expression
In order to determine if the eﬀects of actinomycin D
on leptin secretion were mediated at the transcriptional
level on leptin gene expression, we measured the ex-
pression of both leptin mRNA and 18S RNA by
Northern blot in control and actinomycin D treated
cells. Treatment with actinomycin D for 24 h increased
both basal (223.6 65.2% of control) and insulin-stim-
ulated (128.9 6.9% of insulin-treated cells) leptin
mRNA (Fig. 2A). Treatment with actinomycin D for
48 h totally abolished the eﬀect of insulin to increase
leptin gene expression (Fig. 2B). These ﬁndings are
consistent with the observed eﬀects on leptin secretion.
Actinomycin D did not aﬀect the expression of the 18S
RNA in the presence or absence of insulin.
Eﬀects of actinomycin D on basal and insulin-stimulated
glucose utilization
Results from our previous studies indicated that in-
sulin-stimulated glucose metabolism has an important
role in the regulation of both leptin gene expression and
secretion. Treatment with actinomycin D for 24 h in-
duced a signiﬁcant increase (169.4 16.4%, p < 0:01) of
basal glucose utilization compared to control. Insulin
induced a signiﬁcant stimulation (349.1 33.6%, p <
0:001) in the amount of glucose utilized by the adipo-
cytes, and actinomycin D further stimulated glucose
utilization compared to insulin treatment alone during
the ﬁrst 24 h (124.7 4.3% of insulin-treated cells;
p < 0:01) (Fig. 3A). The amount of glucose utilized by
adipocytes between 24 and 48 h was not signiﬁcantly
aﬀected by actinomycin D in the presence or absence of
insulin (Fig. 3B).
Eﬀects of DRB on basal and insulin-stimulated leptin
secretion
In order to determine if the early stimulatory eﬀect of
actinomycin D on leptin expression and secretion was
due to its transcriptional inhibitory properties, we ex-
amined the eﬀect of 100 lM DRB, an inhibitor of
transcription that acts through a diﬀerent mechanism
than that of actinomycin D, on leptin secretion at 24 and
Fig. 3. Eﬀects of actinomycin D on basal and insulin-stimulated glu-
cose utilization. (A) Glucose utilization after 24 and 48 h of treatment.
(B) Glucose utilization between 24 and 48 h of treatment. Isolated
adipocytes were incubated for up to 48 h in the absence or presence of
insulin (1.6 nM) with actinomycin D (5lg/ml). N ¼ 13 for 24 h and
N ¼ 10 for 48 h. *p < 0:05; **p < 0:01, and ***p < 0:001 compared to
basal control. a and b: p < 0:05; p < 0:01 compared with the 1.6 nM
insulin-treated control.
Fig. 2. Eﬀects of actinomycin D on basal and insulin-stimulated leptin mRNA, as assessed by Northern blots (A and B) after 24 (n ¼ 3) and 48 h
(n ¼ 2) of treatment. The expression level of 18S ribosomal RNA was determined and used as an internal control to correct for minor variation in
total RNA amount. Densitometric scanning was used to determine the relative amount of leptin mRNA and 18 S RNA (C and D).
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inhibit the transcription of several genes in adipocytes
during even shorter time periods [23,24].
The eﬀect of DRB on both basal and insulin-stimu-
lated leptin secretion was similar to what was observedfor actinomycin D at both 24 and 48 h. Treatment for
24 h with DRB (100 lM) signiﬁcantly increased basal
(175.4 18.2% of control, p < 0:01) and insulin-stimu-
lated leptin secretion (141.0 11.1% of insulin-treated
cells, p < 0:05). Basal leptin secretion was unaﬀected by
DRB treatment between 24 and 48 h. Insulin-stimulated
increase of leptin secretion was completely blocked by
DRB treatment (21.9 5.6% of insulin-treated cells,
p < 0:001) (Fig. 4) and the 24–48 h leptin production
was similar to that observed in the absence of insulin.
Eﬀects of cycloheximide on basal and insulin-stimulated
leptin secretion
The eﬀects of cycloheximide, an inhibitor of protein
synthesis, on both basal and insulin-stimulated leptin
secretion were studied at diﬀerent periods of treatment
(4–48 h). Cycloheximide signiﬁcantly decreased both
basal (39.0 10.5% of basal, p < 0:05) and insulin-
stimulated (29.1 11.0% of control, p < 0:001) leptin
secretion during the ﬁrst 4 h of treatment (Fig. 5). The
inhibition of leptin secretion by cycloheximide was even
greater during 24 h and longer periods of treatment
(data not shown). These results indicate that de novo
protein synthesis is required for both basal and insulin-
stimulated leptin secretion.
Eﬀects of cycloheximide on the actions of actinomycin D
on leptin secretion
To further investigate the mechanisms underlying the
paradoxical short-term stimulation of leptin secretion
induced by actinomycin D, we examined the eﬀects of
Fig. 4. Eﬀects of DRB on basal and insulin-stimulated leptin secretion.
Isolated adipocytes were incubated for up to 48 h in the absence or
presence of insulin (1.6 nM) with DRB (100lM). N ¼ 6 in all groups.
*p < 0:05, **p < 0:01, and ***p < 0:001 compared to basal control. a
and c: p < 0:05; p < 0:001 compared with the 1.6 nM insulin-treated
control.
Fig. 5. Eﬀects of cycloheximide on both basal and insulin-stimulated
leptin secretion. Isolated adipocytes were incubated for up to 24 h in
the absence or presence of insulin (1.6 nM) with cycloheximide (10 lg/
ml). N ¼ 12 in all groups. *p < 0:05, **p < 0:01, and ***p < 0:001
compared to control. c: p < 0:001 compared with the 1.6 nM insulin-
treated group, respectively.
Fig. 6. Eﬀects of cycloheximide on the actions of actinomycin D on
basal and insulin-stimulated leptin secretion. Isolated adipocytes were
incubated for 24 h in the absence or presence of insulin (1.6 nM) with
or without actinomycin D (5lg/ml) and/or cycloheximide (10lg/ml).
N ¼ 12 in all groups. *p < 0:05 and ***p < 0:001 compared to basal
control. c: p < 0:001 compared with the 1.6 nM insulin-treated control.
v: p < 0:001 compared with the actinomycin treatment. 1: p < 0:001
compared to the actinomycin+ insulin treatment.
Fig. 7. Eﬀects of cycloheximide on the actions of actinomycin D on
basal and insulin-stimulated glucose utilization. Isolated adipocytes
were incubated for 24 h in the absence or presence of insulin (1.6 nM)
with or without actinomycin D (5lg/ml) and/or cycloheximide (10lg/
ml). N ¼ 12 in all groups. **p < 0:01 and ***p < 0:001 compared to
basal control. a: p < 0:05 compared with the 1.6 nM insulin-treated
control.
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ment completely prevented the eﬀect of actinomycin D
to increase either basal or insulin-stimulated leptin se-
cretion at 24 h of treatment (Fig. 6). These data suggest
that the early stimulation of leptin secretion induced by
actinomycin D requires de novo protein synthesis.
Eﬀects of cycloheximide on the actions of actinomycin D
on glucose utilization
Cycloheximide did not have any signiﬁcant eﬀect on
the amount of glucose utilized at 24 h. However, cyclo-
heximide prevented the short-term increase of glucose
utilization induced by actinomycin D (Fig. 7).Discussion
Our previous results demonstrated that increased
glucose metabolism mediates the long-term eﬀects of
insulin to stimulate leptin secretion in rat cultured
adipocytes. This stimulation of leptin secretion was ac-
companied by a glucose-metabolism dependent increase
of leptin mRNA expression [12]. Other studies exam-
ining the eﬀects of insulin and glucose on leptin gene
expression and secretion have reported similar results
[7,14,15,25]. Together, these data suggest that a
transcriptional mechanism mediates the eﬀect of insulin-
stimulated glucose metabolism to increase leptin pro-
duction. This is further supported by studies showing
that the activity of the leptin promoter in transfected
cells is increased by insulin and glucose [17] and this
increase is dependent on increased glucose metabolism
[18]. However, it is possible that glucose and insulin also
induce a post-transcriptional stabilization of the leptin
mRNA which could contribute to increased leptin
production.
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lation of leptin secretion, we examined the short- and
long-term eﬀects of actinomycin D, an inhibitor of
transcription, on leptin expression and secretion. The
concentration of actinomycin D used in this study (5 lg/
ml) has been previously employed in several studies to
determine the role of transcription in the regulation of
leptin or other adipocyte genes [26,27]. Short-term
treatments (4 and 24 h) with actinomycin D increased
both leptin expression and secretion. A similar eﬀect of
actinomycin D on leptin has been previously reported by
Fain and Bahouth [28], and more recently by Bradley
and Cheatham [19]. Hardie et al. [10] observed a sig-
niﬁcant decrease in leptin after actinomycin treatment
from the ﬁrst hours of treatment. This result may be due
to the higher concentration of actinomycin (10 lg/ml)
employed in that study.
Actinomycin D has been previously reported to
inhibit the transcription of several adipocytes genes,
including fatty acid synthase and pref-1 [29,30]. In fact,
the studies of Fain and Bahouth [28] and Bradley and
Cheatham [19] conﬁrmed that actinomycin D inhibited
the transcription of GAPDH and C/EBPd, respectively,
at the same time when leptin mRNA expression was
increased. This suggests that the increase of both leptin
mRNA and secretion results from a speciﬁc eﬀect of
actinomycin on the leptin gene.
Bradley and Cheatham [19] suggest that actinomycin
D may inhibit a short-lived regulatory protein that
either represses transcription of the leptin gene or desta-
bilizes the message. Fain and Bahouth [28] suggest that
actinomycin D stabilizes leptin mRNA and therefore
increases leptin release. Alterations of mRNA stability
have been described as a universal post-transcriptional
mechanism for modulating gene expression [31]. In
support of this idea, several studies have shown that
actinomycin D can prevent the destabilization of neu-
roﬁlament mRNA in primary sensory neurons [32] as
well as stabilize the urokinase mRNA in macrophages
[33]. DRB may have a similar eﬀect. The mechanisms
underlying the alteration of mRNA stability remain yet
unclear. Regarding the possibility that actinomycin D
may interfere with a factor that represses transcription,
Wang et al. [34] have identiﬁed a negative cis-acting
element located in the mouse leptin promoter that is
repressed by insulin and glucose. It is possible that ac-
tinomycin D and DRB induce a short-term stimulation
of leptin expression by repressing the binding of a
transcription factor to this element.
Our previous studies [12] have shown that insulin-
mediated glucose metabolism plays a key role in regu-
lating both leptin gene expression and secretion in
isolated rat adipocytes. Wellhoener et al. [13] have also
provided evidence that glucose metabolism is an im-
portant determinant of insulin-mediated leptin secretion
in humans. We observed that actinomycin D induced asigniﬁcant increase in both basal and insulin-stimulated
glucose utilization after 24 h. In addition, between 24
and 48 h of treatment when the stimulatory eﬀects of
actinomycin D on glucose utilization are no longer
present, the stimulatory eﬀect on leptin secretion dis-
appears. In addition, treatment with cycloheximide,
which blocks the stimulatory eﬀects of actinomycin D
on glucose utilization at 24 h, also prevents its stimula-
tory action on leptin secretion. These results suggest that
the mechanism by which actinomycin D increases leptin
secretion and expression may be mediated by glucose
metabolism. However, DRB, which also induces a
short-term stimulation of leptin secretion, did not aﬀect
glucose uptake (data not shown). Therefore, it is unclear
whether the stimulatory eﬀect of actinomycin involves a
mechanism related to glucose metabolism or is related to
its properties to inhibit transcription.
Between 24 and 48 h of treatment, the stimulatory
eﬀect of actinomycinDandDRBonbasal leptin secretion
disappeared and leptin secretionwas similar in the control
and actinomycin-treated cells. Between 24 and 48 h, ac-
tinomycin D and DRB totally prevented the increases of
leptin mRNA expression and leptin secretion induced by
insulin-mediated glucose metabolism. Neither actino-
mycin D nor DRB aﬀected basal or insulin-stimulated
glucose utilization during this time period. These results,
along with the work of Fukuda and Iritani [17] and Mo-
reno-Aliaga et al. [18], strongly support a transcriptional
mechanism by which glucose and insulin increase long-
term leptin production. Fukuda and Iritani [17] reported
that insulin and glucose activate the leptin promoter in rat
adipocytes. Wang et al. [34] suggested that insulin and
glucose stimulate mouse leptin gene expression by
repressing the binding of a transcription factor to its
negative cis-acting element of the leptin promoter. In
addition, our previous experiments in 3T3-L1 adipocytes
[18], and our recent data in primary cultured rat adipo-
cytes [35], demonstrate that the activation of the promoter
is mediated by the eﬀects of insulin to increase cellular
glucose utilization.
While the available data strongly support a tran-
scriptional regulatory mechanism for insulin-mediated
glucose metabolism to increase leptin production, it
remains to be determined whether activation of tran-
scription by insulin-mediated glucose metabolism is due
to stimulation of transcriptional co-activators or due to
the inhibition of transcriptional co-repressor. Further
experiments are required to more precisely deﬁne the
transcriptional mechanism underlying the stimulatory
eﬀect of glucose and insulin on leptin expression.
With the present data, a possible post-transcriptional
mechanism by which increased leptin mRNA stability
increases leptin production during the ﬁrst 24 h of
treatment cannot be ruled out.
Inhibition of protein synthesis with cycloheximide
blocked leptin secretion within the ﬁrst 4 h of treatment,
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insulin and glucose to stimulate leptin production. A
previous study [19] also showed that cycloheximide in-
hibits leptin secretion. However, these authors also re-
ported that insulin could increase leptin secretion in the
presence of cycloheximide, possibly from a preexisting
intracellular pool. Another study [20] has identiﬁed a
leptin-containing intracellular compartment in rat adi-
pose cells and showed that cycloheximide did not prevent
serum-induced acute increase in leptin secretion. How-
ever, a more recent study by Levy and Stevens [36] pro-
vides additional evidence against the release of leptin from
a preformed intracellular pool in response to insulin and
glucose. These investigators examined both leptin secre-
tion and intracellular leptin and observed that cyclohex-
imide completely blocks leptin synthesis and leptin
secretion in response to the metabolic secretagogues
(glucose, insulin, and pyruvate). They concluded that the
secretagogues increased leptin secretion by increasing
leptin synthesis rather than enhancing the release of a
preexisting cytosolic pool [36]. These authors attributed
the conﬂicting results to diﬀerences in the method of in-
cubation with cycloheximide. For the two earlier studies
[19,20], cells were incubated with cycloheximide for only
20min, washed, and then re-incubated with fresh media
without cycloheximide. For both the Levy and Stevens
[36] and present study, the cells were incubated continu-
ously in the presence of cycloheximide.
In summary, the results of these experiments provide
evidence that glucose metabolism regulates leptin ex-
pression and secretion at the level of transcription.
Further experiments are required to determine the
mechanisms and transcription factors underlying the
eﬀects of insulin-stimulated glucose metabolism on lep-
tin gene expression. The possibility of a post-transla-
tional regulatory mechanism during the ﬁrst 24 h cannot
be excluded. De novo protein synthesis is required for
insulin and insulin-mediated glucose metabolism to in-
crease leptin production.Acknowledgments
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